Novel compositions and methods

a heterocycle fused and gamma-aminobutyric acid technology, applied in the field of substitution of heterocycle fused gamma-aminobutyric acid, can solve the problems of no cure or standard treatment for dementia, drug compositions, side effects that do not treat affective symptoms and/or other behavior disruptions, and achieve the effects of reducing behavioral disturbances, reducing side effects, and reducing side effects

a heterocycle fused and gamma-aminobutyric acid technology, applied in the field of substitution of heterocycle fused gamma-aminobutyric acid, can solve the problems of no cure or standard treatment for dementia, drug compositions, side effects that do not treat affective symptoms and/or other behavior disruptions, and achieve the effects of reducing behavioral disturbances, reducing side effects, and reducing side effects

US20150080404A1Inactive Publication Date: 2015-03-19INTRA CELLULAR THERAPIES INC
6 Cites 74 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel compositions and methods
  • Novel compositions and methods
  • Novel compositions and methods

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effect of Compound A on Reversal of Social Isolation resulted from Repeated Stress

[0105]Mice are tested for social isolation behavior after repeated exposure (once daily for 10 days) to an aggressive resident intruder mouse in the social defeat / resident intruder paradigm as describe by Berton et al., Science (2006) 311:864-868, the contents of which are incorporated by reference. Mice are then dosed chronically, once daily for 30 d, with either vehicle (5% DMSO / 5% Tween-20 / 15% PEG400 / 75% water, 6.7 ml / kg volume) or Compound A (1 mg / kg, ip) in vehicle solution. On the day after the last drug or vehicle treatment, the mice are placed in the open field in the presence of a resident intruder mouse and the animal's behavior recorded by videotape for 10 min. The videotapes are then scored for the total time each mouse spent during a 10 min period in specified open-field quadrants. The total time (sec) spent by mice representing each drug treatment group in the Interaction Zone in proximit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
physicalaaaaaaaaaa
binding affinityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation / aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a national phase application filed under 35 U.S.C. §371 of International Application No. PCT / US2013 / 036515, filed on Apr. 14, 2013, which International Application claims priority from U.S. Provisional Application Nos. 61 / 624,293, 61 / 624,292 and 61 / 624,291, all filed on Apr. 14, 2012; and U.S. Provisional Application Nos. 61 / 671,723 and 61 / 671,713, both filed on Jul. 14, 2012, the contents of each of which are incorporated by reference in their entirety.TECHNICAL FIELD[0002]The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same, optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation / aggression), psychosis, de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
19 Mar 2015
Publication
US20150080404A1
IPC
C07D471/16; A61K31/4985; A61K31/445
CPC
C07D471/16; A61K31/4985; A61K31/445; A61K45/06; A61K31/5383; A61P21/02; A61P25/00; A61P25/06
Inventors
MATES, SHARON; DAVIS, ROBERT